HCPLive

FEBRUARY 5, 2024

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

Blood Pressure 116

Blood Pressure Obesity Diabetes 116

HCPLive

FEBRUARY 14, 2024

Patients with ACPA-positive RA and obesity had greater DAS44 scores compared to normal-weight patients, although this difference was not present in ACPA-negative RA.

Obesity 105

Obesity 105

American Heart News - Heart News

FEBRUARY 5, 2024

Research Highlights: The weight loss medication tirzepatide significantly lowered the systolic blood pressure of nearly 500 adults who had obesity and took the medication for 36 weeks, or about eight months, in a subset of an international clinical.

Blood Pressure 121

Blood Pressure Obesity Research 121

American Heart News - Heart News

JANUARY 17, 2024

Research Highlights: Consistently high scores of perceived stress during adolescence through adulthood may contribute to worse cardiometabolic health including obesity in young adults. Researchers suggest the adoption of healthy coping strategies.

Obesity 126

Obesity Blood Pressure Diabetes Research 126

Journal of Clinical Investigation - Cardiology

FEBRUARY 1, 2024

Nonalcoholic fatty liver disease (NAFLD) is prevalent in the majority of individuals with obesity, but in a subset of these individuals, it progresses to nonalcoholic steatohepatitis (0NASH) and fibrosis. The mechanisms that prevent NASH and fibrosis in the majority of patients with NAFLD remain unclear.

Obesity 109

Obesity Diet 109

Med Page Today

MARCH 8, 2024

(MedPage Today) -- Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like semaglutide (Wegovy) are facing a new dilemma: What happens if they stop taking them? Many worry, rightly, that they'll.

Obesity 105

Obesity 105

Cardiovascular Diabetology

APRIL 1, 2024

Obesity is often associated with multiple comorbidities. However, whether obese subjects with hyperlipidemia in the absence of other complications have worse cardiac indices than metabolically healthy obese su.

Obesity 84

Obesity Research 84

Medical Xpress - Cardiology

JANUARY 16, 2024

Obesity-induced heart disease, which affects up to 10% of the population in certain age ranges, is considered an untreatable condition and 75% of people don't survive more than five years beyond diagnosis.

Obesity 91

Obesity Heart Disease Research 91

HCPLive

APRIL 28, 2024

This observational cohort study looked at the link between obesity and eczema, highlighting regional differences in the skin disease and obesity’s interdependence.

Obesity 52

Obesity 52

American College of Cardiology

APRIL 10, 2024

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?

Preserved Ejection Fraction 57

Preserved Ejection Fraction Obesity Heart Failure Diabetes 57

HCPLive

APRIL 20, 2024

During this segment of her interview at the ACP Internal Medicine Meeting, Jay discussed improving obesity care, telehealth utilization for patients, and more.

Obesity 59

Obesity 59

Science Daily - Heart Disease

JANUARY 17, 2024

Young adults who reported higher stress as adolescents were more likely to have high blood pressure, obesity and other cardiometabolic risk factors as adults, finds new study.

Blood Pressure 94

Blood Pressure Obesity Diabetes Risk Factors 94

CardiacWire

DECEMBER 6, 2023

The already massive GLP-1 obesity drug segment might have gained a major future competitor last week, following Roche’s acquisition of weight loss biotech Carmot Therapeutics. The biotech also has a once-daily dual GLP-1/GIP injectable (yes, daily) that’s in Phase 2 trials and would treat obese or overweight patients with type 1 diabetes.

Obesity 59

Obesity Diabetes 59

Frontiers in Cardiovascular Medicine

MARCH 7, 2024

We initiated a mobilization program, but the patient's mobility was highly limited due to severe obesity and symptomatic orthostatic hypotension. B-SES could be an option for patients with heart failure who have limited mobility and obesity. B-SES was introduced to accomplish weight loss and early ambulation.

Heart Failure 124

Heart Failure Obesity Heart Transplant Transplant 124

Frontiers in Cardiovascular Medicine

APRIL 18, 2024

BackgroundAtrial fibrillation (AF) is a common cardiac arrhythmia that is associated with obesity and obstructive sleep apnea syndrome (OSA). The study utilized GWAS data and applied various statistical methods for the analysis.ResultsThe study found that obesity increased the risk of OSA, which in turn significantly increased the risk of AF.

Obesity 52

Obesity Atrial Fibrillation Arrhythmia Research 52

HCPLive

APRIL 22, 2024

Thorndike discussed highlights from her ACP 2024 talk titled ‘Annals Beyond the Guidelines: How Would You Treat this Patient with Obesity?’

Obesity 52

Obesity 52

HCPLive

APRIL 8, 2024

Obesity was linked to a lower likelihood of obtaining response to treatment during the 48-week follow-up period.

Obesity 69

Obesity Risk Factors 69

Medical Xpress - Cardiology

JANUARY 17, 2024

Young adults who reported higher stress during their teenage years to adulthood were more likely to have high blood pressure, obesity and other cardiometabolic risk factors than their peers who reported less stress, according to new research published in the Journal of the American Heart Association.

Blood Pressure 92

Blood Pressure Obesity Diabetes Risk Factors 92

HCPLive

APRIL 19, 2024

Lopez discusses the growing prevalence of obesity in the US and the need for improved, cross-specialty care based on patients’ metabolic health.

Obesity 59

Obesity 59

American College of Cardiology

MARCH 6, 2024

Bariatric surgery is effective in controlling hypertension (HTN) and polypharmacy in patients with obesity, according to results from the GATEWAY clinical trial published Feb. 5 in JACC.

Obesity 68

Obesity Hypertension Article 68

Frontiers in Cardiovascular Medicine

FEBRUARY 7, 2024

Background Aging is associated with a higher prevalence of sarcopenia, sarcopenic obesity (SO), and increased arterial stiffening, with possible detrimental effects on morbidity and mortality. The population was sorted into four subgroups: obese, sarcopenic, SO, and controls. SO had the highest value of cfPWV (15.18 ± 8.44 m/s),

Obesity 64

Obesity Hospital 64

Journal of Clinical Investigation - Cardiology

FEBRUARY 15, 2024

Melanocortin 4 receptor (MC4R) mutations are the most common cause of human monogenic obesity and are associated with hyperphagia and increased linear growth. While MC4R is known to activate Gsα/cAMP signaling, a substantial proportion of obesity-associated MC4R mutations do not affect MC4R/Gsα signaling.

Obesity 75

Obesity 75

American College of Cardiology

MARCH 12, 2024

What are the trends in the estimated prevalence of underweight and obesity from 1990 to 2022 among adults and children across 200 countries and territories?

Obesity 48

Obesity Article 48

American College of Cardiology

APRIL 6, 2024

The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).

Preserved Ejection Fraction 68

Preserved Ejection Fraction Obesity Heart Failure Diabetes 68

HCPLive

JANUARY 24, 2024

Addressing isolation and loneliness indexes resulted in a decreased risk of all-cause mortality among individuals with obesity in the UK Biobank.

Obesity 59

Obesity 59

American College of Cardiology

JANUARY 8, 2024

Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovascular disease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.

Obesity 70

Obesity Atrial Fibrillation Heart Failure Risk Factors 70

Frontiers in Cardiovascular Medicine

JANUARY 31, 2024

Obesity, a pervasive health concern, has been identified as a significant risk factor for ATAAD, introducing unique surgical challenges that can influence postoperative outcomes. Based on BMI (WS/T 428-2013), patients were categorized into normal weight, overweight, and obese. Results The average age of the cohort was 50.1 ± 11.2

Obesity 64

Obesity Aortic BMI Outcomes 64

NEJM Journal Watch - Cardiology

MAY 2, 2024

A pooled analysis from two harmonized, industry-funded trials shows improved obesity and symptoms and markers of HFpEF.

Obesity 45

Obesity Diabetes 45

Journal of the American Heart Association

DECEMBER 29, 2023

Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. In particular, expanding epicardial adipose tissue during obesity has been suggested as a key driver of AF via paracrine signaling and direct infiltration.

Obesity 45

Obesity Atrial Fibrillation Heart Failure Pharmacology 45

Cardiology Update

DECEMBER 11, 2023

Previous studies have associated obesity with negative changes in the right ventricle using imaging techniques. However, the connection between obesity and more direct measures of right ventricle function, particularly those reflecting hemodynamic consequences, have been unclear. Original article: Circ Heart Fail. 2023;16:e010524.

Obesity 52

Obesity Hospital Outcomes Heart Failure 52

Frontiers in Cardiovascular Medicine

DECEMBER 13, 2023

Background The obesity occurrence has achieved epidemic levels worldwide and several studies indicate a paradoxical similarity among obesity and the prognosis in heart failure (HF). Conclusion In not hospitalized patients with HFREF of ischemic etiology, obesity was not a protective factor.

Outpatient 59

Outpatient Obesity Heart Failure BMI 59

HCPLive

JANUARY 11, 2024

For every increment increase in a participant’s usual score for depressive symptoms, investigators of a new study found weight increased a month later by 45g, only for participants with overweight and obesity.

Obesity 52

Obesity 52

HeartRhythm

APRIL 30, 2024

Obesity is reported as a worsening factor for atrial tachyarrhythmia (AT) recurrence after AF ablation. However, the impact of obesity on FPI has been scarcely reported. General anesthesia (GA) seems to facilitate completing PVI in obese patients by preventing airway obstruction caused by sedative drug use during the procedure.

Obesity 40

Obesity Pulmonary Ablation Atrial Fibrillation 40

HeartRhythm

APRIL 30, 2024

However, the role of MS and diabetes in predicting HF outcomes was not assessed in non-obese patients. We have previously shown an association between metabolic syndrome (MS) and heart failure (HF) outcomes in patients with implanted defibrillators (ICD) and cardiac resynchronization therapy (CRT-D).

Obesity 40

Obesity Heart Failure Diabetes Outcomes 40

HeartRhythm

APRIL 30, 2024

Evidence supports the relationship between obesity and the incidence and recurrence of Afib. Catheter Ablation for Atrial Fibrillation (AFib) in heart failure is now a class I indication for patients with heart failure.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Obesity Ablation 40

American College of Cardiology

JANUARY 2, 2024

The goal of the SURMOUNT-4 trial was to evaluate tirzepatide compared with placebo among obese patients.

Obesity 60

Obesity Article 60

Cardiometabolic Health Congress

JULY 25, 2023

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52